Tara Rheault Selected Research

ensifentrine

1/2021	A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy.
1/2020	Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD - A Detailed Analysis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tara Rheault Research Topics

Disease

3	Chronic Obstructive Pulmonary Disease (COPD) 01/2021 - 04/2016
1	Inflammation (Inflammations) 01/2021
1	Dyspnea (Shortness of Breath) 01/2020

Drug/Important Bio-Agent (IBA)

2	ensifentrineIBA 01/2021 - 01/2020
2	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2021 - 01/2020
1	Tiotropium Bromide (Spiriva)FDA Link 01/2021
1	Bronchodilator Agents (Bronchodilators)IBA 01/2020
1	GSK573719IBA 04/2016
1	Glycopyrrolate (Glycopyrronium Bromide)FDA LinkGeneric 04/2016

Therapy/Procedure

1	Therapeutics 01/2021